TGF-β antagonists: Why suppress a tumor suppressor?

Journal of Clinical Investigation

Volumn 109, Issue 12, 2002, Pages 1533-1536

  Akhurst, Rosemary J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ANTAGONIST DERIVATIVE; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; METASTASIS; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0036084359     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215970     Document Type: Note

References (20)

1. TGF-β signaling in tumor suppression and cancer progression
2. TGF-β signaling in cancer: A double-edged sword
3. TGF-β signaling: Positive and negative effects on tumorigenesis
4. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways
5. TGFβ stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways
6. Elevated levels of activated Smad2 and H-ras control epithelial-mesenchymal transformation, tumor cell extravasation and metastasis
7. Blockade of TGF-β inhibits mammary rumor cell viability, migration, and metastases
8. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
9. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
10. Transforming growth factorβ1 is a new form of tumor suppressor with true haploid insufficiency
11. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis
12. Cyclosporine induces cancer progression by a cell-autonomous mechanism
13. Decorin gene transfermediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo
14. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy
15. Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation
16. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells
17. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion
18. Loss of thyrotropin regulation and transforming growth factor βinduced growth arrest in erbB-2 overexpressing rat thyroid cells
19. Induction of angiogenesis by expression of soluble type II transforming growth factor-β receptor in mouse hepatoma
20. The ErbB receptor family: A therapeutic target for cancer